行情中心 沪深京A股 上证指数 板块行情 股市异动 专题 涨跌情报站 盯盘 港股 研究所 直播 股票开户 智能选股
全球指数
数据中心 资金流向 龙虎榜 融资融券 沪深港通 比价数据 研报数据 公告掘金 新股申购 大宗交易 业绩速递

UNITED IMAGING(688271):STRONG 2025 RESULTS DRIVEN BY OVERSEAS EXPANSION AND DOMESTIC SHARE GAINS

招银国际证券有限公司 04-29 00:00

United Imaging (UIH) reported strong 2025 results. Revenue rose 34.0% YoY to RMB13.8bn, 4% above our estimate, while attributable net profit increased 48.1% YoY to RMB1.9bn. In 1Q26, revenue grew 17.3% YoY to RMB2.9bn, slightly missing our expectation, accounting for 17% of our full-year forecast (vs. the historical average of ~20%). We therefore lower our 2026E revenue growth forecast from 25.7% to 22.5% YoY, although our absolute revenue estimate increases by 1.4% on a higher base in 2025.

Overseas expansion remains the key growth driver. Overseas revenue rose 51.4% YoY to RMB3.4bn in 2025, driven by strong growth across major regions, including North America (+56% YoY), Europe (+50% YoY), and APAC (+41% YoY). Momentum remained solid in 1Q26, with overseas revenue up ~27% YoY to approximately RMB710mn. In our view, the strong performance was driven by continued progress in high-end products such as PET/CTs and MRs, as well as improving global sales and service network. Overseas service revenue grew ~53% YoY in 2025. With rising brand recognition and increasing penetration into high-end customers, we expect overseas revenue to maintain robust growth in 2026E.

Domestic growth was driven by market share gains. Domestic revenue grew 29.1% YoY to RMB10.4bn in 2025, with UIH ranking No.1 in new installations across multiple products, including CT, MR, MI and RT. Share gains were particularly notable in MR (+6.4ppts), RT (+18.1ppts), and PET/CT (+13.5ppts). Looking ahead, equipment renewal projects are continuing to roll out. With the implementation experience in 2025, we expect the execution to accelerate and continue to support hospital procurement demand. However, the domestic market for medical imaging equipment declined 21.1% YoY in 1Q26, according to MDDi. Therefore, we believe that UIH’s revenue growth will face tougher comparisons in 2H26E given the lags between tender wins and revenue recognition.

Near-term GPM headwinds partially offset by favorable product mix. GPM declined 1.5ppts/2.8ppts YoY to 47.0%/47.2% in 2025/1Q26, respectively, mainly due to domestic VBPs, tariffs and higher liquid helium costs. Encouragingly, blended ASP increased by more than 20% YoY in 2025, driven by a richer mix of high-end systems. For example, revenue from 3.0T-andabove MR systems grew over 60% YoY and accounted for over two thirds of total MR revenue in 2025. Service revenue, which carries higher GPM than equipment sales, rose 26% YoY and accounted for 12.4% of total revenue in 2025. We believe that the mix shift toward high-end systems and services should help partially offset pressure from VBPs, tariffs, and elevated liquid helium costs. More diversified helium sourcing and greater in-house production of key components should also support margin improvement.

Maintain BUY. We remain positive on UIH’s long-term growth. However, we lower our 2026-28E earnings forecasts to factor in VBP pressure and elevated liquid helium costs in the near term. We therefore lower TP to RMB161.04 based on a 9-year DCF model (WACC: 8.1%, terminal growth: 4.0%).

免责声明:以上内容仅供您参考和学习使用,任何投资建议均不作为您的投资依据;您需自主做出决策,自行承担风险和损失。九方智投提醒您,市场有风险,投资需谨慎。

相关股票

相关板块

  • 板块名称
  • 最新价
  • 涨跌幅

相关资讯

扫码下载

九方智投app

扫码关注

九方智投公众号

头条热搜

涨幅排行榜

  • 上证A股
  • 深证A股
  • 科创板
  • 排名
  • 股票名称
  • 最新价
  • 涨跌幅
  • 股圈